News

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with Amgen (NASDAQ:AMGN).

Over the past six months, Fastly’s shares (currently trading at $6.33) have posted a disappointing 14% loss while the S&P 500 was down 3.4%. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the vertical software industry, including Alarm.com (NASDAQ:ALRM) and its peers.

JLL trades at $244.01 per share and has stayed right on track with the overall market, losing 7.8% over the last six months while the S&P 500 is down 3.4%. This might have investors contemplating their next move.

What a brutal six months it’s been for The Real Brokerage. The stock has dropped 27.1% and now trades at $4.09, rattling many shareholders. This may have investors wondering how to approach the situation.

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the testing & diagnostics services stocks, including NeoGenomics (NASDAQ:NEO) and its peers.

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how consumer internet stocks fared in Q4, starting with Coinbase (NASDAQ:COIN).